



## References

1. Boozalis E, Tang O, Patel S, et al. Ethnic differences and comorbidities of 909 prurigo nodularis patients. *J Am Acad Dermatol*. 2018;79(4):714-719.e3. doi:10.1016/j.jaad.2018.04.047
2. Cevikbas F, Wang X, Akiyama T, et al. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. *J Allergy Clin Immunol*. 2014;133(2):448-460. doi:10.1016/j.jaci.2013.10.048
3. Choi JE, Di Nardo A. Skin neurogenic inflammation. *Semin Immunopathol*. 2018;40(3):249-259. doi:10.1007/s00281-018-0675-z
4. Datsi A, Steinhoff M, Ahmad F, Alam M, Buddenkotte J. Interleukin-31: The "itchy" cytokine in inflammation and therapy. *Allergy*. 2021;76(10):2982-2997. doi:10.1111/all.14791
5. DUPIXENT (prescribing information). Bridgewater, NJ: Sanofi-Aventis; Sep 2022.
6. Elmariah S, Kim B, Berger T, et al. Practical approaches for diagnosis and management of prurigo nodularis: United States expert panel consensus. *J Am Acad Dermatol*. 2021;84(3):747-760. doi:10.1016/j.jaad.2020.07.025
7. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI)--a simple practical measure for routine clinical use. *Clin Exp Dermatol*. 1994;19(3):210-216. doi:10.1111/j.1365-2230.1994.tb01167.x
8. Galderma announces positive data from phase III OLYMPIA 2 trial in adults with prurigo nodularis. Galderma. Updated July 4, 2023. Accessed Aug 15, 2023. <https://www.galderma.com/news/galderma-wcd-2023-late-breaking-phase-iii-results-nemolizumab-monootherapy-prurigo-nodularis>
9. Garcovich S, Maurelli M, Gisondi P, Peris K, Yosipovitch G, Girolomoni G. Pruritus as a distinctive feature of type 2 inflammation. *Vaccines (Basel)*. 2021;9(3):303. doi:10.3390/vaccines9030303
10. Hashimoto T, Nattkemper LA, Kim HS, et al. Itch intensity in prurigo nodularis is closely related to dermal interleukin-31, oncostatin M, IL-31 receptor alpha and oncostatin M receptor beta. *Exp Dermatol*. 2021;30(6):804-810. doi:10.1111/exd.14279
11. Huang AH, Canner JK, Khanna R, Kang S, Kwatra SG. Real-world prevalence of prurigo nodularis and burden of associated diseases. *J Invest Dermatol*. 2020;140(2):480-483.e4. doi:10.1016/j.jid.2019.07.697
12. Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Ständer S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. *J Eur Acad Dermatol Venereol*. 2013;27(5):550-557. doi:10.1111/j.1468-3083.2012.04481.x
13. Inan S, Torres-Huerta A, Jensen LE, Dun NJ, Cowan A. Nalbuphine, a kappa opioid receptor agonist and mu opioid receptor antagonist attenuates pruritus, decreases IL-31, and increases IL-10 in mice with contact dermatitis. *Eur J Pharmacol*. 2019;864:172702. doi:10.1016/j.ejphar.2019.172702
14. Johansson O, Liang Y, Marcusson JA, Reimert CM. Eosinophil cationic protein- and eosinophil-derived neurotoxin/eosinophil protein X-immunoreactive eosinophils in prurigo nodularis. *Arch Dermatol Res*. 2000;292(8):371-378. doi:10.1007/s004030000142

## Prurigo Nodularis: Recognizing, Diagnosing and Treating a Rare but Debilitating Disease



15. Kwatra SG. Breaking the itch-scratch cycle in prurigo nodularis. *N Engl J Med*. 2020;382(8):757-758. doi:10.1056/NEJMe1916733
16. Kwon CD, Khanna R, Williams KA, Kwatra MM, Kwatra SG. Diagnostic workup and evaluation of patients with prurigo nodularis. *Medicines (Basel)*. 2019;6(4):97. Published 2019 Sep 26. doi:10.3390/medicines6040097
17. Liang Y, Jacobi HH, Reimert CM, Haak-Frendscho M, Marcusson JA, Johansson O. CGRP-immunoreactive nerves in prurigo nodularis - An exploration of neurogenic inflammation. *J Cutan Pathol*. 2000;27(7):359-366. doi:10.1034/j.1600-0560.2000.027007359.x
18. Magand F, Nacher M, Cazorla C, Cambazard F, Marie DS, Couppié P. Predictive values of prurigo nodularis and herpes zoster for HIV infection and immunosuppression requiring HAART in French Guiana. *Trans R Soc Trop Med Hyg*. 2011;105(7):401-404. doi:10.1016/j.trstmh.2011.04.001
19. Matsunaga K, Katoh N, Fujieda S, Izuhara K, Oishi K. Dupilumab: Basic aspects and applications to allergic diseases. *Allergol Int*. 2020;69(2):187-196. doi:10.1016/j.alit.2020.01.002
20. Pereira MP, Steinke S, Zeidler C, et al. European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. *J Eur Acad Dermatol Venereol*. 2018;32(7):1059-1065. doi:10.1111/jdv.14570
21. Phan NQ, Blome C, Fritz F, et al. Assessment of pruritus intensity: prospective study on validity and reliability of the visual analogue scale, numerical rating scale and verbal rating scale in 471 patients with chronic pruritus. *Acta Derm Venereol*. 2012;92(5):502-507. doi:10.2340/00015555-1246
22. Sofen H, Bissonnette R, Yosipovitch G, et al. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor  $\beta$  antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study. *EClinicalMedicine*. 2023;57:101826. doi:10.1016/j.eclinm.2023.101826
23. Ständer HF, Elmariah S, Zeidler C, Spellman M, Ständer S. Diagnostic and treatment algorithm for chronic nodular prurigo. *J Am Acad Dermatol*. 2020;82(2):460-468. doi:10.1016/j.jaad.2019.07.022
24. Ständer S, Pereira MP, Berger T, et al. IFSI-guideline on chronic prurigo including prurigo nodularis. *Itch*. 2020;5(4):1-13. doi:10.1097/itx.0000000000000042
25. Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate-to-severe prurigo nodularis. *N Engl J Med*. 2020;382(8):706-716. doi:10.1056/NEJMoa1908316
26. Steinke S, Zeidler C, Riepe C, et al. Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial. *J Am Acad Dermatol*. 2018;79(3):457-463.e5. doi:10.1016/j.jaad.2018.04.044
27. Tsianakas A, Zeidler C, Ständer S. Prurigo nodularis management. *Curr Probl Dermatol*. 2016;50:94-101. doi:10.1159/000446049
28. Weisshaar E, Szepietowski JC, Bernhard JD, et al. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase. *J Eur Acad Dermatol Venereol*. 2022;36(3):453-461. doi:10.1111/jdv.17816

## Prurigo Nodularis: Recognizing, Diagnosing and Treating a Rare but Debilitating Disease



29. Williams KA, Roh YS, Brown I, et al. Pathophysiology, diagnosis, and pharmacological treatment of prurigo nodularis. *Expert Rev Clin Pharmacol*. 2021;14(1):67-77. doi:10.1080/17512433.2021.1852080
30. Yosipovitch G, Mollanazar N, Ständer S, et al. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials. *Nat Med*. 2023;29(5):1180-1190. doi:10.1038/s41591-023-02320-9
31. Zhong W, Wu X, Zhang W, et al. Aberrant expression of histamine-independent pruritogenic mediators in keratinocytes may be involved in the pathogenesis of prurigo nodularis. *Acta Derm Venereol*. 2019;99(6):579-586. doi:10.2340/00015555-3150